Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01859962 · ClinicalTrials.gov registry record · Phase 2
Study of PPI-668, BI 207127 and Faldaprevir, With and Without Ribavirin, in the Treatment of Chronic Hepatitis C
A Phase 2 study, sponsored by Presidio Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 38
- Enrollment target
NCT01859962 is a Phase 2 study that has completed, run by Presidio Pharmaceuticals. The registered enrollment target is 38 participants.
The verdict
NCT01859962, a Phase 2 study, has completed, sponsored by Presidio Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 38 participants
- Enrollment target
Study Summary
This study is designed to provide a preliminary assessment of the safety and effectiveness of the combination of PPI-668, BI 207127 and faldaprevir, with or without ribavirin, in the treatment of chronic hepatitis C virus infection.
Interventions
- DRUG Ribavirin
- DRUG Faldaprevir
- DRUG PPI-668
- DRUG BI 207127 Dose 1
- DRUG BI 207127 Dose 2
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2013-05 |
| Est. Completion | 2014-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01859962
The ClinicalTrials.gov registry entry for NCT01859962 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 38 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Presidio Pharmaceuticals, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Ribavirin is the first listed.
NCT01859962 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01859962 about?
NCT01859962 is a clinical study titled "Study of PPI-668, BI 207127 and Faldaprevir, With and Without Ribavirin, in the Treatment of Chronic Hepatitis C". This study is designed to provide a preliminary assessment of the safety and effectiveness of the combination of PPI-668, BI 207127 and faldaprevir, with or without ribavirin, in the treatment of chronic hepatitis C virus infection.
What is the current status of trial NCT01859962?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 38 participants. The study started on 2013-05. Estimated completion is 2014-12.
What interventions are being tested in trial NCT01859962?
The interventions under investigation include: Ribavirin (DRUG), Faldaprevir (DRUG), PPI-668 (DRUG), BI 207127 Dose 1 (DRUG), BI 207127 Dose 2 (DRUG).
Who is sponsoring clinical trial NCT01859962?
This trial is sponsored by Presidio Pharmaceuticals, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.